Use of Continuous Venovenous Hemodiafiltration with a High Cutoff Membrane in a Patient with Severe Acute Pancreatitis

Cosimo Chelazzi, Dario Giugni, Claudia Giannoni, Gianluca Villa, Angelo Raffaele De Gaudio

Department of Critical Care, Anesthesiology and Intensive Care Section, University of Florence, Florence, Italy.

DOI: 10.4236/ojneph.2012.24013                

Abstract

In patients with severe acute pancreatitis (SAP) early and persistent elevated circulating levels of interleukins (IL)-1, 2 and 6 and tumor necrosis factor (TNF)-α are linked to severity of disease and early multiple organ failure (MOF), while persistently elevated serum IL-10 is linked to immune paralysis and infectious complications. Although experimental and clinical evidence exists that continuous venovenous hemodiafiltration with high cutoff membranes (HCO-CVVHDF) efficiently removes inflammatory mediators from blood of patients with severe sepsis or septic shock, data are lacking on the subset of patients with SAP, particularly in cases with uninfected necrosis. We treated with HCO-CVVHDF a 59-year-old man admitted to our intensive care unit (ICU) with SAP inducing early-onset cardiovascular, respiratory and renal dysfunctions associated with high circulating levels of IL-6 and TNF-α and without overt clinical or laboratory signs of infection. During the treatment, cardiovascular, respiratory and renal functions rapidly normalized and circulating levels of IL-6 and TNF-α consistently decreased. The patient was discharged from ICU on day 20.

Keywords

Acute Pancreatitis; Multiple Organ Failure; Blood Purification

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M.-L. Kyl?np??, H. Repo and P. A. Puolakkainen, “Inflammation and Immunosuppression in Severe Acute Pancreatitis,” World Journal of Gastroenterology, Vol. 16, No. 23, 2010, pp. 2867-2872. doi:10.3748/wjg.v16.i23.2867
[2]	J. Granger and D. Remick, “Acute Pancreatitis: Models, Markers, and Mediators,” Shock, Vol. 24, Suppl. 1, 2005, pp. 45-51. doi:10.1097/01.shk.0000191413.94461.b0
[3]	R. P. Dellinger, M. M. Levy, J. M. Carlet, J. Bion, M. M. Parker, R. Jaeschke, et al., “Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,” Critical Care Medicine, Vol. 36, No. 1, 2008, pp. 1394-1396. doi:10.1097/01.CCM.0000298158.12101.41
[4]	K. Wada, T. Takada, K. Hirata, T. Mayumi, M. Yoshida, M. Yokoe, et al., “Treatment Strategy for Acute Pancreatitis,” Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 17, No. 1, 2009, pp. 79-86 doi:10.1007/s00534-009-0218-z
[5]	R. Bellomo, C. Ronco, J. A. Kellum, R. L. Mehta, P. Palevsky and Acute Dialysis Quality Initiative Workgroup, “Acute Renal Failure—Definition, Outcome Measures, Animal Models, Fluid Therapy and Information Technology Needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group,” Critical Care, Vol. 8, No. 4, 2004, pp. 204-212. doi:10.1186/cc2872
[6]	M. Bhatia, F. L. Wong, Y. Cao, H. Y. Lau, J. Huang, P. Puneet, et al., “Pathophysiology of Acute Pancreatitis,” Pancreatology, Vol. 5, No. 2-3, 2005, pp. 132-144. doi:10.1159/000085265
[7]	C. Martin, C. Boisson, M. Haccoun, L. Thomachot and J. L. Mege, “Patterns of Cytokine Evolution (Tumor Necrosis Factor-Alpha and Interleukin-6) after Septic Shock, Hemorrhagic Shock, and Severe Trauma,” Critical Care Medicine, Vol. 25, No. 11, 1997, pp. 1813-1819. doi:10.1097/00003246-199711000-00018
[8]	H. G. Leser, V. Gross, C. Scheibenbogen, A. Heinisch, R. Salm, M. Lausen, et al., “Elevation of Serum Interleukin-6 Concentration Precedes Acute-Phase Response and Reflects Severity in Acute Pancreatitis,” Gastroenterology, Vol. 101, No. 3, 1991, pp. 782-785.
[9]	C. Ronco, C. Tetta, F. Mariano, M. L. Wratten, M. Bonello, V. Bordoni, et al., “Interpreting the Mechanisms of Continuous Renal Replacement Therapy in Sepsis: The Peak Concentration Hypothesis,” Artificial Organs, Vol. 27, No. 9, 2003, pp. 792-801. doi:10.1046/j.1525-1594.2003.07289.x
[10]	S. Oda, T. Sadahiro, Y. Hirayama, M. Nakamura, E. Watanabe, Y. Tateishi, et al., “Non-Renal Indications for Continuous Renal Replacement Therapy: Current Status in Japan,” Contributions to Nephrology, Vol. 166, 2010, pp. 47-53. doi:10.1159/000314851
[11]	H. Hirasawa, “Indications for Blood Purification in Critical Care,” Contributions to Nephrology, Vol. 166, 2010, pp. 21-30. doi:10.1159/000314847
[12]	D. Gong, P. Zhang, D. Ji, Z. Chen, W. Li , J. Li, et al., “Improvement of Immune Dysfunction in Patients with Severe Acute Pancreatitis by High-Volume Hemofiltration: A Preliminary Report,” The International Journal of Artificial Organs, Vol. 33, No. 1, 2010, pp. 22-29.
[13]	R. Abe, S. Oda, K. Shinozaki and H. Hirasawa, “Continuous Hemodiafiltration Using a Polymethyl Methacrylate Membrane Hemofilter for Severe Acute Pancreatitis,” Contributions to Nephrology, Vol. 166, 2010, pp. 54-63. doi:10.1159/000314852
[14]	S. Morgera, T. Slowinski, C. Melzer, V. Sobottke, O. Vargas-Hein, T. Volk, et al., “Renal Replacement Therapy with High Cutoff Hemofilters: Impact of Convection and Diffusion on Cytokine Clearances and Protein Status,” American Journal of Kidney Diseases, Vol. 43, No. 3, 2004, pp. 444-453. doi:10.1053/j.ajkd.2003.11.006
[15]	J. Zhang, C. Yuan, G. Hua, R. Tong, X. Luo and Z. Ying, “Early Gut Barrier Dysfunction in Patients with Severe Acute Pancreatitis: Attenuated by Continuous Blood Purification Treatment,” The International Journal of Artificial Organs, Vol. 33, No. 10, 2010, pp. 706-715.
[16]	D. N. Cruz, M. Antonelli, R. Fumagalli, F. Foltran, N. Brienza, A. Donati, et al., “Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock: The EUPHAS Randomized Controlled Trial,” The Journal of the American Medical Association, Vol. 301, No 23, 2009, pp. 2445-2452. doi:10.1001/jama.2009.856
[17]	H. L. Jiang, W. J. Xue, D. Q. Li, A. P. Yin, X. Xin, C. M. Li, et al., “Influence of Continuous Veno-Venous Hemofiltration on the Course of Acute Pancreatitis,” World Journal of Gastroenterology, Vol. 11, No. 31, 2005, pp. 4815-4821.
[18]	J. Cohen and J. Carlet, “INTERSEPT: An International, Multicenter, Placebo-Controlled Trial of Monoclonal Antibody to Human Tumor Necrosis Factor-Alpha in Patients with Sepsis. International Sepsis Trial Study Group,” Critical Care Medicine, Vol. 24, No. 9, 1996, pp. 1431-1440. doi:10.1097/00003246-199609000-00002
[19]	J. F. Dhainaut, J. L. Vincent, C. Richard, P. Lejeune, C. Martin, L. Fierobe, et al., “CDP571, a Humanized Antibody to Human Tumor Necrosis Factor-Alpha: Safety, Pharmacokinetics, Immune Response, and Influence of the Antibody on Cytokine Concentrations in Patients with Septic Shock. CPD571 Sepsis Study Group,” Critical Care Medicine, Vol. 23, No. 9, 1995, pp. 1461-9. doi:10.1097/00003246-199509000-00004
[20]	K. Reinhart, C. Wiegand-L?hnert, F. Grimminger, M. Kaul, S. Withington, D. Treacher, et al., “Assessment of the Safety and Efficacy of the Monoclonal Anti-Tumor Necrosis Factor Antibody-Fragment, MAK 195F, in Patients with Sepsis and Septic Shock: A Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study,” Critical Care Medicine, Vol. 24, No. 5, 1996, pp. 733-742. doi:10.1097/00003246-199605000-00003